PEDIATRICS Vol. 55 No. 5 May 1975, pp. 678-685
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ch'ien, L. T.
Right arrow Articles by Alford, C. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ch'ien, L. T.
Right arrow Articles by Alford, C. A., Jr.

Antiviral Chemotherapy and Neonatal Herpes Simplex Virus Infection: A Pilot Study—Experience With Adenine Arabinoside (ARA-A)

Lawrence T. Ch'ien M.D.1, Richard J. Whitley M.D.1, Andre J. Nahmias M.D.1, Edward B. Lewin M.D.1, Calvin C. Linnemann Jr. M.D.1, Lawrence D. Frenkel M.D.1, Joseph A. Bellanti M.D.1, Robert A. Buchanan M.D.1, and Charles A. Alford Jr. M.D.1

1 Department of Pediatrics, University of Alabama, Birmingham; Emory University, Atlanta; the University of Cincinnati, Cincinnati, Ohio; Georgetown University, Washington, D.C.; the University of Rochester, Rochester, New York; and Parke, Davis and Co., Ann Arbor, Michigan

Among 13 neonates with herpes simplex virus (HSV) infection, eight had disseminated disease, one localized CNS disease, and in four the infection was confined to the skin and eyes. Ara-A, a purine nucleoside with anti-viral activity against DNA-viruses, was given (10 to 20 mg/kg/ day) by a continuous 12-hour intravenous drip for 10 to 15 days. In all, ara-A administration was begun within three to eight days after the appearance of skin vesicles which represented the hallmark of the disease. Both diagnosis and ara-A treatment were much delayed in one infant without skin vesicles and four infants whose skin vesicles appeared late, long after the occurrence of CNS damage. In this group of infants with disseminated disease, four died and one infant was left with severe neurological deficits.

Eight infants (four with disseminated and four with localized skin disease) with skin vesicles as the earliest sign of infection received ara-A early, within three days after the onset of neurologic signs. All survived with no neurologic deficit at 6 months to 1 year of age. There was no apparent toxicity of ara-A to the bone marrow, liver, or kidney.

Submitted on July 16, 1974
Accepted on September 12, 1974